Skip to main content

and
  1. No Access

    Article

    Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study

    Patients affected by heart failure with reduced ejection fraction (HFrEF) receive clinical and functional beneficial effects from treatment with sacubitril/valsartan. However previous studies have shown that p...

    Matteo Casale, Michele Correale, Giulia Laterra in Clinical Drug Investigation (2021)

  2. No Access

    Article

    Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Ezetimibe reduces plasma low-density lipoprotein cholesterol (LDL-C) levels by up to 20%. However, its effect on plasma lipoprotein(a) [Lp(a)] concentrations in patients with primary hypercholesterolemia has n...

    Kamal Awad, Dimitri P. Mikhailidis, Niki Katsiki, Paul Muntner, Maciej Banach in Drugs (2018)

  3. No Access

    Chapter

    Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

    Simvastatin and fenofibrate are the most frequently co-prescribed drugs for the treatment of dyslipidemia, manifesting beneficial effects on non-lipid parameters as well. The combination of these two drugs has...

    Dragana Nikolic, Niki Katsiki, Peter P. Toth MD, PhD in Combination Therapy In Dyslipidemia (2015)

  4. No Access

    Article

    Role of Antihypertensive Drugs in Arterial ‘De-Stiffening’ and Central Pulsatile Hemodynamics

    Arterial stiffness is an independent predictor of cardiovascular (CV) morbidity and mortality in patients with hypertension, as well as a potential therapeutic target. There is increasing awareness that the pu...

    Charalambos Koumaras, Maria Tzimou in American Journal of Cardiovascular Drugs (2012)